Overview

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Loteprednol Etabonate